75290-62-9

Usage

Uses

Used in Pharmaceutical Applications:
N-(N-TRIFLUOROACETYL-L-CYSTEINYL)-GLYCINE METHYL ESTER is used as a prodrug for enhancing the bioavailability of NAC, allowing for improved therapeutic effects in treating various conditions.
Used in Respiratory Disease Treatment:
N-(N-TRIFLUOROACETYL-L-CYSTEINYL)-GLYCINE METHYL ESTER is used as a therapeutic agent for respiratory diseases, leveraging its antioxidant properties to mitigate oxidative stress associated with these conditions.
Used in Liver Disorder Management:
N-(N-TRIFLUOROACETYL-L-CYSTEINYL)-GLYCINE METHYL ESTER is used as a hepatoprotective agent, potentially aiding in the treatment of liver disorders by supporting liver function and reducing oxidative damage.
Used in Neurodegenerative Disease Research:
N-(N-TRIFLUOROACETYL-L-CYSTEINYL)-GLYCINE METHYL ESTER is used as a research compound for exploring its potential in treating neurodegenerative diseases, due to its antioxidant properties that may protect neurons from oxidative stress.
Used in Organic Chemistry:
N-(N-TRIFLUOROACETYL-L-CYSTEINYL)-GLYCINE METHYL ESTER is used as a reagent in the synthesis of other compounds, contributing to the development of new chemical entities for various applications.

InChI:InChI=1/C8H11F3N2O4S/c1-17-5(14)2-12-6(15)4(3-18)13-7(16)8(9,10)11/h4,18H,2-3H2,1H3,(H,12,15)(H,13,16)/t4-/m0/s1

Upstream product

• 89422-41-3 bis-N-trifluoroacetylcysteinyl-bis-glycine dimethyl ester 
• 402-91-5 N-Trifluoracetyl-L-cystine 
• 53267-37-1 N,N'-Bis-trifluoracetyl-L-cystylchlorid 

Downstream Products

• 73836-78-9 (7E,9E,11Z,14Z)-6-[2-Amino-2-(carboxymethyl-carbamoyl)-ethylsulfanyl]-5-hydroxy-icosa-7,9,11,14-tetraenoic acid 
• 118683-85-5 N--N-(trifluoroacetyl)-L-cysteinyl>glycine methyl ester 
• 75290-64-1 (5Z,8Z,10E,12E)-(14S,15R)-14-[(S)-2-Amino-2-(carboxymethyl-carbamoyl)-ethylsulfanyl]-15-hydroxy-icosa-5,8,10,12-tetraenoic acid 
• 73836-78-9 Leukotriene D 
• 33467-76-4 (E)-hept-2-en-1-ol 
• 118682-94-3 N--L-cysteinyl>glycine 
• 73836-78-9 leukotriene D4 

Relevant academic research and scientific papers

Total synthesis of leukotrienes from butadiene

The total synthesis of leukotrienes has been achieved starting from butadiene by a palladium-catalyzed telomerization at room temperature. A Sharpless catalytic asymmetric epoxidation generated the asymmetric centers with >94% ee. Simple transformations of the key intermediate 15 produced the leukotrienes LTA4 methyl ester (4), LTC4 (1), LTD4 (2) and LTE4 (3), as well as (14S, 15S)-LTA4 methyl ester (24) and the novel [2H2]-LTA4 methyl ester (28). The use of the opposite chiral director in the Sharpless catalytic asymmetric epoxidation gave the key intermediate 15a that has been used in the synthesis of the double epimers of the leukotrienes as well as LTB4.

4-oxo-benzopyran carboxylic acids

Compounds of the Formula I: STR1 and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.

Total synthesis of slow reacting substances (SRS). "Leukotriene C-2" (11-trans-leukotriene C) (3) and leukotriene D (4)

Syntheses are described for the "slow reacting substances" 11-trans-leukotriene C (3) (previously known as leukotriene C-2) and leukotriene D (4), the cys-gly analog of leukotriene C (2). The synthesized leukotrienes 3 and 4 were instrumental in the assignment of structure to these members of the family of naturally occuring slow reacting substances which includes also 2.